Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women
Authors' conclusion
Romosozumab following denosumab improved LS BMD and TBS greater than denosumab continuation in postmenopausal women.
Study context
- Population
- Postmenopausal women who initiated denosumab between 2017 and 2020matched cohort
- Participants
- 86 vs 86
- Exposure
- Romosozumab after denosumab vs denosumab continuation
- DRn = 86
- DDn = 86reference
- Outcome
- LS BMD gain post-transition
- Follow-up
- 12 mo post-transition
Main finding
As reported in the abstract
DR
+6.8
% point
DD
+3.3
% point
P < 0.001
Observational data: associations, not effects.
Further findings
TBS improvement
P = 0.042
| Outcome | DR | DD | P value |
|---|---|---|---|
| Overall LS BMD gain | +11.6% | +8.0% | P < 0.001 |
Hip bone mineral density (BMD) · 12 mo post-transition
- DD: continued improvement of hip BMD; DR: hip BMD maintained but not improved
Bone turnover markers after transition to romosozumab · 1 month after transition
- P1NP increased above level at denosumab initiation with relatively suppressed CTx (transient anabolic window)
BMD gain by denosumab from initiation to transition (matched DR and DD) · median 4 times [range 2-8]
- Mean lumbar spine (LS) BMD gain
- +4.8%
- Mean total hip BMD gain
- +2.0%
Safety
Incident fractures · 12 mo follow-up
- DD: morphometric vertebral fracture
- 1
- DD: patella fracture
- 1
- DR: ankle fracture
- 1
Original publication
Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women. J Bone Miner Res. Published 1 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →